Evidence map›Paper›PMID 27631261›Full record

Observational studyMedicine2016

Long-term efficacy and toxicity of abacavir/lamivudine/nevirapine compared to the most prescribed ARV regimens before 2013 in a French Nationwide Cohort Study.

Paul de Boissieu, Moustapha Dramé, François Raffi, André Cabie, Isabelle Poizot-Martin, Laurent Cotte, Rodolphe Garraffo, Pierre Delobel, Thomas Huleux, David Rey and 2 more

Open access · goldAbstract readComparative StudyMulticenter StudyObservational Study
In one paragraph

Observational study in Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Observational
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 2 countries.

Paul de BoissieuDepartment of Research and Innovation, Reims Teaching Hospitals, Robert Debré Hospital Faculty of Medicine, University of Reims Champagne-Ardenne, Reims Department of Infectious Diseases, University Hospital, Nantes Department of Infectious and Tropical Diseases, Martinique Teaching Hospitals, Fort-De-France Hospital, Fort-De-France, Martinique Aix-Marseille University, APHM Hôpital Sainte-Marguerite, Immuno-Hematology Clinic, Marseille, France Inserm U912 (SESSTIM), Marseille, France Hospices Civils de Lyon, Service des Maladies Infectieuses et Tropicales, INSERM U1052, Lyon Laboratoire de pharmacologie, Université de Nice-Sophia-Antipolis, Hôpital Pasteur, CHU de Nice, Nice Cedex 1 CHU de Toulouse, Service des Maladies Infectieuses et Tropicales, INSERM UMR1043, Université Toulouse III Paul Sabatier, Toulouse Centre Hospitalier Tourcoing, Service Universitaire de Maladies Infectieuses et du Voyageur, Tourcoing Le Trait d'Union, Centre de Soins de l'Infection par le VIH, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg Department of Internal Medicine, Infectious Diseases, and Clinical Immunology, Reims Teaching Hospitals, Robert Debré Hospital Faculté de médecine, EA-4684/SFR CAP-SANTE, Université de Reims Champagne-Ardenne, Reims, France.
Moustapha Dramé
François Raffi
André Cabie
Isabelle Poizot-Martin
Laurent Cotte
Rodolphe Garraffo
Pierre Delobel
Thomas Huleux
David Rey
Firouzé Bani-Sadr
Dat’AIDS Study Group
Université de Reims Champagne-Ardenne · FRAix-Marseille Université · FRCentre Hospitalier de Tourcoing · FRCentre Hospitalier Universitaire de Martinique · MQHôpital Civil, Strasbourg · FRHôpital Pasteur · FRHôpital Robert-Debré · FRInserm · FRUniversité Toulouse III - Paul Sabatier · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Data on the long-term efficacy and safety of abacavir/lamivudine (ABC/3TC) and nevirapine (NVP) are scarce. This combination has the advantage of simplifying treatment and improving long-term tolerance. The aim of this study was to compare the rate of any discontinuation of antiretroviral (ARV) regimen because of virologic failure (VF), and/or adverse drug reaction (ADR) among patients receiving stable ARV regimens for at least 6 months.ABC/3TC/NVP was compared to ABC/3TC with either ritonavir-boosted darunavir (DRV/r) or ritonavir-boosted atazanavir (ATV/r), unboosted ATV, or tenofovir/emtricitabine (TDF/FTC) with either one of the following: ATV/r, unboosted ATV, DRV/r, efavirenz (EFV), or NVP, in the French prospective multicenter Dat'AIDS cohort.The study enrolled 16,511 patients treated with following ARV regimens: ABC/3TC/NVP (n = 1089), TDF/FTC/NVP (n = 1542), ABC/3TC/DRV/r (n = 1065), ABC/3TC/ATV/r (n = 1847), ABC/3TC/ATV (n = 563), TDF/FTC/ATV/r (n = 3519), TDF/FTC/DRV/r (n = 2767), TDF/FTC/ATV (n = 419), and TDF/FTC/EFV (n = 3700). Mean follow-up was 36 ± 24 months. Patients treated with ABC/3TC/NVP received this regimen as a switch regimen in 97% of cases. By multivariable analysis, the risk of treatment discontinuation due to VF was similar between ABC/3TC/NVP and other ARV regimens, except for TDF/FTC/ATV and ABC/3TC/ATV, which were associated with a higher risk of treatment interruption due to VF (hazard ratio [HR] 1.99; 95% confidence interval [CI] 1.29-3.06 and HR 2.19; 95% CI 1.51-3.18, respectively). Treatment discontinuation due to ADR was lowest with the ABC/3TC/NVP regimen. Other ARV regimens were associated with a 1.80- to 3.19-fold increase in the risk of treatment discontinuation due to ADR (P < 0.0001 for all comparisons).ABC/3TC/NVP as a simplification regimen is a long-term effective regimen with lower discontinuation due to long-term toxicity compared with other standard ARV regimens.

Indexed as

AbacavirAdultDideoxynucleosidesDrug Therapy, CombinationFemaleFranceHIV InfectionsHumansLamivudineMaleMiddle AgedNevirapineProspective StudiesReverse Transcriptase InhibitorsTreatment OutcomeAbacavirDideoxynucleosidesLamivudineNevirapineReverse Transcriptase Inhibitors

Identifiers

PMID27631261
PMCPMC5402604
OpenAlexW2520170146

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.